Research programme: protease enzyme inhibitors - Paradigm Therapeutics
Latest Information Update: 13 Feb 2008
At a glance
- Originator Paradigm Therapeutics
- Developer Takeda Cambridge
- Class Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Cancer; Viral infections
Most Recent Events
- 27 Apr 2007 No development reported - Preclinical for Bacterial infections in United Kingdom (unspecified route)
- 27 Apr 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
- 27 Apr 2007 No development reported - Preclinical for Viral infections in United Kingdom (unspecified route)